Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Amarin (AMRN) NCE Delay Not all Negative - MKM Partners
June 18, 2013 12:13 PM EDTMKM Partners analyst Jon LeCroy weighed in on Amarin (NASDAQ: AMRN) Tuesday following news that NCE status on Vascepa was once again delayed. LeCroy said the NCE... More
